Radiology Partners acquires healthcare AI company Cognita Imaging

Mosaic, the technology and AI services division of Radiology Partners (RP), announced the acquisition of Cognita Imaging for $80 million.

Cognita, founded last year by Stanford scientists, builds medical vision-language models and clinical AI tools. RP has already been using the company’s models to power Mosaic Drafting, which analyzes X-rays and head CTs and prepares preliminary results for physicians to review and confirm.  The tool has been tested across 95,000 exams by more than 100 radiologists, showing read-time reductions of up to 76% and improved detection rates of up to 52%

“The next era of radiology will be defined by the convergence of clinical expertise and advanced technology. With imaging demand rising much faster than radiologist supply, the combination of Mosaic and Cognita strengthens our ability to transform how care is delivered—improving accuracy, accelerating time-to-diagnose and expanding access to high-quality imaging. Together, we aim to deliver better outcomes for patients and health systems at scale, while equipping radiologists with the tools to deliver faster, more precise care, while mitigating clinician burnout.” – Rich Whitney, CEO of Mosaic and RP.

“Nearly half of the world’s population has limited or no access to basic diagnostics. Cognita is committed to accelerating access to imaging care across the world, and joining forces with Mosaic allows us to apply our technology at scale for impact while preserving the cutting-edge technology development, rapid innovation and best-in-class AI talent that defines our company. We’re excited to continue growing a world-class AI engineering team as we bring the next generation of AI-powered tools into widespread clinical practice as part of the MosaicOS™ platform.” – Louis Blankemeier, CEO of Cognita.

Cognita will continue operating as an independent business unit at RP. The deal gives Cognita access to RP’s dataset of 55 million annual imaging studies as it advances its models through FDA trials and brings more AI-driven diagnostic tools into clinical practice.